TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25329681

Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone Propionate Combination (SFC) 50/100 µg once daily for 12 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Inhaled Salmeterol (SAL) 50 µg twice daily for 12 weeks
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Discontinuation of both treatments after 12 weeks
Number of subjects: 43
Study: 22092536

Group type: EXPERIMENTAL
Intervention: Paracetamol (APAP 1 g) + Saline (placebo)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (pl) + Saline (placebo)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Paracetamol (APAP 1 g) + Naloxone (Nal 8 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (pl) + Naloxone (Nal 8 mg)
Number of subjects: 12
Study: 21854752

Group type: EXPERIMENTAL
Intervention: Clodronate (CLO) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: PBS treatment
Number of subjects: 0
Study: 19473513

Group type: EXPERIMENTAL
Intervention: PACAM nutrition supplement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Specially designed exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 17762955

Group type: EXPERIMENTAL
Intervention: General anesthesia with low insufflation pressure (7‐9 mmHg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: General anesthesia with high insufflation pressure (13‐15 mmHg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural analgesia with low insufflation pressure
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: General anesthesia plus epidural analgesia with high insufflation pressure
Number of subjects: 60
Study: 15018027

Group type: EXPERIMENTAL
Intervention: Worksite physical activity counseling (N = 131)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Control group (N = 168)
Number of subjects: 299
Study: 11549415

Group type: EXPERIMENTAL
Intervention: Bovine colostrum whey
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 9931797

Group type: EXPERIMENTAL
Intervention: IMPACT (Test)
Number of subjects: 29

Group type: COMPARATOR
Intervention: isonitrogenous isocaloric diet (Control)
Number of subjects: 29
Study: 7539635

Group type: EXPERIMENTAL
Intervention: FK 506 (tacrolimus) at a starting dose of 0.15 mg/kg/day for 12 months
Number of subjects: 19
Study: 3200556

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Meperidine
Number of subjects: 47

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 47
Study: 31992077

Group type: EXPERIMENTAL
Intervention: Shokti+, a nutritionally fortified yogurt
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Market price of Shokti+
Number of subjects: 1000
Study: 30654054

Group type: EXPERIMENTAL
Intervention: SQ tree SLIT-tablet
Number of subjects: 634

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 634
Study: 28238587

Group type: EXPERIMENTAL
Intervention: 3D full-volume color Doppler transthoracic echocardiography (FVCD)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 2D proximal isovelocity surface area (PISA)
Number of subjects: 152

Group type: COMPARATOR
Intervention: 2D volumetric method (VM)
Number of subjects: 152
Study: 26220564

Group type: EXPERIMENTAL
Intervention: Bite Back positive psychology program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (non-psychology entertainment websites)
Number of subjects: 0
Study: 23414459

Group type: EXPERIMENTAL
Intervention: Random Forest method for detecting response shift in quality of life (QoL)
Number of subjects: 524
Study: 21496517

Group type: EXPERIMENTAL
Intervention: editing‐out‐the‐negative skills training
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: accepting influence skills training
Number of subjects: 100

Group type: COMPARATOR
Intervention: time‐out
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: skills training (both editing-out-the-negative and accepting influence)
Number of subjects: 100
Study: 18563062

Group type: EXPERIMENTAL
Intervention: Alcohol-dependent individuals (ADs)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Stress and alcohol cue exposure
Number of subjects: 34

Group type: COMPARATOR
Intervention: Social drinkers (SDs)
Number of subjects: 34
Study: 17020076

Group type: EXPERIMENTAL
Intervention: scale up on velocity with no instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: maintain constant velocity with no instruction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: maintain constant velocity with instruction
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: scale up on velocity with instruction
Number of subjects: 60
Study: 15527479

Group type: EXPERIMENTAL
Intervention: Out-of-home pre-school day care
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: In-depth interviews with mothers
Number of subjects: 120
Study: 11117247

Group type: EXPERIMENTAL
Intervention: 1.4% glycerol
Number of subjects: 10
Study: 9308793

Group type: EXPERIMENTAL
Intervention: Collagenase type IV
Number of subjects: 20

Group type: COMPARATOR
Intervention: Collagenase type IA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Collagenase type IA supplemented with elastase
Number of subjects: 20

Group type: COMPARATOR
Intervention: Collagenase type IV supplemented with elastase
Number of subjects: 20
Study: 7854920

Group type: EXPERIMENTAL
Intervention: 1 g i.v. acetazolamide
Number of subjects: 29

Group type: COMPARATOR
Intervention: rCBF SPECT and TCD
Number of subjects: 29
Study: 2671560

Group type: EXPERIMENTAL
Intervention: 6 months supervised daily RMP 600 mg, ETH 500 mg and DDS 100 mg or CLO 100 mg followed by 6 months unsupervised daily DDS 100 mg or CLO 100 mg with ETH 500 mg added or not
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: 6 months supervised daily RMP 600 mg, ETH 500 mg and DDS 100 mg or CLO 100 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: 6 months unsupervised daily DDS 100 mg or CLO 100 mg with ETH 500 mg added or not
Number of subjects: 289
Study: 920841

Group type: EXPERIMENTAL
Intervention: 500 mg/day of disulfiram
Number of subjects: 81

Group type: COMPARATOR
Intervention: 250 mg/day of disulfiram
Number of subjects: 81

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 81
Study: 31351548

Group type: EXPERIMENTAL
Intervention: High-Intensity Respiratory Muscle Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28107822

Group type: EXPERIMENTAL
Intervention: Training course (1.5 hours)
Number of subjects: 286
Study: 26818683

Group type: EXPERIMENTAL
Intervention: Internet-based stress management intervention (iSMI)
Number of subjects: 264
Study: 23891363

Group type: EXPERIMENTAL
Intervention: Fenofibric acid (FA) 45 mg + Rosuvastatin (R) 5 mg for 8 weeks, then 10 mg for 8 additional weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rosuvastatin (R) 5 mg for 8 weeks, then 10 mg for 8 additional weeks
Number of subjects: 0
Study: 21606149

Group type: EXPERIMENTAL
Intervention: EMONO (50% nitrous oxide and 50% oxygen)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (50% nitrogen and 50% oxygen)
Number of subjects: 100
Study: 19484433

Group type: EXPERIMENTAL
Intervention: IDD Therapy (Intervertebral Differential Dynamics Therapy) with traction weight systematically increased until 50% of a person's body weight plus 4.45 kg (10 lb) was reached.
Number of subjects: 60

Group type: COMPARATOR
Intervention: SHAM group with a non‐therapeutic traction weight of 4.45 kg in all sessions.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IDD Therapy and SHAM group (both groups received standard conservative therapeutic care and 20 sessions).
Number of subjects: 60
Study: 16624438

Group type: EXPERIMENTAL
Intervention: Insulin sensitivity formula proposed by McAuley
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 72
Study: 14560062

Group type: EXPERIMENTAL
Intervention: Galantamine 24 mg/day
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo to Galantamine (open-label phase)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Galantamine (continuous treatment)
Number of subjects: 285
Study: 11708713

Group type: EXPERIMENTAL
Intervention: Small Increment (SI) progressive resistance exercise
Number of subjects: 19

Group type: COMPARATOR
Intervention: Traditional (TRAD) progressive resistance exercise
Number of subjects: 19
Study: 8702377

Group type: EXPERIMENTAL
Intervention: Random practice
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Blocked practice
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 2008110

Group type: EXPERIMENTAL
Intervention: Low-dose allopurinol (total dose 1200 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: High-dose allopurinol (total dose 2400 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No allopurinol
Number of subjects: 90
Study: 7123294

Group type: EXPERIMENTAL
Intervention: Lidocaine mixed with contrast medium
Number of subjects: 34
Study: 31846898

Group type: EXPERIMENTAL
Intervention: Communication of the diagnosis of PNES
Number of subjects: 54

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 54
Study: 30362173

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg
Number of subjects: 909
Study: 28934640

Group type: EXPERIMENTAL
Intervention: rhIGF-1/rhIGFBP-3
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard neonatal care
Number of subjects: 19
Study: 25294666

Group type: EXPERIMENTAL
Intervention: Strength RT with 60‐s rest intervals (SS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Strength RT with 4‐min rest intervals (SL)
Number of subjects: 22
Study: 23416318

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) on the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study: 22428485

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg/kg bolus followed by 0.4 microg/kg/hr infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study: 19398283

Group type: EXPERIMENTAL
Intervention: Baclofen (20mg q.i.d. titrated upwards over twelve days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 17312229

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 176

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 176
Study: 15193851

Group type: EXPERIMENTAL
Intervention: Hawaii Healthy Start Program (HSP)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 643
Study: 11641075

Group type: EXPERIMENTAL
Intervention: Intrarectal quinine (QIR) 20 mg/kg in solution with 2 ml of water, followed by 15 mg/kg/8 h for cerebral malaria; 30 mg/kg followed by 20 mg/kg/12 h for severe malaria.
Number of subjects: 133

Group type: COMPARATOR
Intervention: Intrarectal quinine (QIR)
Number of subjects: 133
Study: 9613298

Group type: EXPERIMENTAL
Intervention: Isoflurane (0.3, 0.6, 0.9, 1.2 vol.%)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Desflurane (1.5, 3.0, 4.5, 6.0 vol.%)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.5, 1.0, 1.5, 2.0 vol.%)
Number of subjects: 36
Study: 7906384

Group type: EXPERIMENTAL
Intervention: Didanosine (500 mg per day)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Zalcitabine (2.25 mg per day)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 467
Study: 1982648

Group type: EXPERIMENTAL
Intervention: Potenlini treatment (daily intravenous drip of 60‐100 ml for 3 days)
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control group (other measures of treatment same as therapeutic group)
Number of subjects: 439
Study: 230693

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 micrograms + levonorgestrel 125 micrograms (50/125)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 50 micrograms + levonorgestrel 250 micrograms (50/250)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol 30 micrograms + levonorgestrel 150 micrograms (30/150)
Number of subjects: 75
Study: 30868787

Group type: EXPERIMENTAL
Intervention: Open treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Closed treatment
Number of subjects: 0
Study: 27773578

Group type: EXPERIMENTAL
Intervention: PMA + RA (n = 48)
Number of subjects: 96

Group type: COMPARATOR
Intervention: RA alone (n = 48)
Number of subjects: 96
Study: 23096064

Group type: EXPERIMENTAL
Intervention: Low amplitude group (GL)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: High amplitude group (GH)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 38
Study: 21663459

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study: 19846008

Group type: EXPERIMENTAL
Intervention: Low-stretch group (pressure assist control mode with peak pressure not higher than 35 cm H(2)O or pressure support mode with Pplateau not higher than 30 cm H(2)O)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Low-tidal-volume group (tidal volume no more than 6 ml/kg of predicted body weight)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low-stretch group
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low-stretch subgroup (V(T)e ≤6 ml/kg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Non-low-tidal-volume subgroup (V(T)e >6 ml/kg)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low-tidal-volume subgroup (V(T)e ≤6 ml/kg)
Number of subjects: 85
Study: 17241418

Group type: EXPERIMENTAL
Intervention: Topical botulinum toxin type A (BTX‐A) 200 U applied to one axilla
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vehicle without BTX‐A applied to the other axilla
Number of subjects: 12
Study: 15027057

Group type: EXPERIMENTAL
Intervention: Dysport
Number of subjects: 164

Group type: COMPARATOR
Intervention: BOTOX
Number of subjects: 164
Study: 11686231

Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori with lansoprazole and antibiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Acid-suppressant treatment alone (lansoprazole)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eradication of H. pylori
Number of subjects: 0
Study: 9231834

Group type: EXPERIMENTAL
Intervention: Lisinopril (10, 20, or 40 mg)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5, 25, or 50 mg)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232
Study: 8136647

Group type: EXPERIMENTAL
Intervention: Mixt. 716 treatment group
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mixt. 716
Number of subjects: 150
Study: 3524840

Group type: EXPERIMENTAL
Intervention: Etretinate therapy (4 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (4 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (after etretinate therapy)
Number of subjects: 15
Study: 29504793

Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive-behavioral treatment (ICBT) with systematic exposure
Number of subjects: 309

Group type: COMPARATOR
Intervention: Internet-delivered cognitive-behavioral treatment (ICBT) without exposure (ICBT-WE)
Number of subjects: 309
Study: 27664129

Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 78
Study: 23711620

Group type: EXPERIMENTAL
Intervention: Whole body vibration training (squat positioned on a vibration platform, 3 times per week for 11 weeks)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 49
Study: 22052452

Group type: EXPERIMENTAL
Intervention: ronacaleret 100 mg once daily
Number of subjects: 569

Group type: COMPARATOR
Intervention: teriparatide 20 µg subcutaneously once daily
Number of subjects: 569

Group type: COMPARATOR
Intervention: alendronate 70 mg once weekly
Number of subjects: 569

Group type: EXPERIMENTAL
Intervention: ronacaleret
Number of subjects: 569

Group type: COMPARATOR
Intervention: teriparatide
Number of subjects: 569

Group type: COMPARATOR
Intervention: alendronate
Number of subjects: 569
Study: 19462823

Group type: EXPERIMENTAL
Intervention: Tamsulosin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Eviprostat
Number of subjects: 0
Study: 17452893

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) with corticosteroids
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cyclosporine (CsA) with corticosteroids
Number of subjects: 44
Study: 15103688

Group type: EXPERIMENTAL
Intervention: Acellular vaccine for children >4 years of age, adolescents, and adults
Number of subjects: 100
Study: 11669028

Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) 400 mg suspension every six months plus Vitamin A 2 ml (1 ml for infants)
Number of subjects: 2010

Group type: COMPARATOR
Intervention: Control group received Vitamin A 2 ml (1 ml for infants) every six months
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: Albendazole (ABZ) plus Vitamin A
Number of subjects: 2010
Study: 9850906

Group type: EXPERIMENTAL
Intervention: Sutureless closure
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intraoperatively adjusted cross suture
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Unadjusted cross suture
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sutured cases
Number of subjects: 75
Study: 7991321

Group type: EXPERIMENTAL
Intervention: Test-retest reliability
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Parent-teacher agreement
Number of subjects: 66
Study: 2733949

Group type: EXPERIMENTAL
Intervention: Immediate oxytocin induction (86 women)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Expectant management with oxytocin induction at 24 hours if labor had not occurred spontaneously (96 women)
Number of subjects: 182
Study: 6340081

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 147
Study: 30295729

Group type: EXPERIMENTAL
Intervention: Positive Mood and Active Life (PMAL) program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 68
Study: 31271338

Group type: EXPERIMENTAL
Intervention: Previously medicated patients
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Antipsychotic-naïve patients
Number of subjects: 226
Study: 27660922

Group type: EXPERIMENTAL
Intervention: Occupational therapy (twice a day for 5 days)
Number of subjects: 140
Study: 27059671

Group type: EXPERIMENTAL
Intervention: HydE (9 g daily for 6 months)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: HydE
Number of subjects: 29
Study: 24311763

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg daily for 3 months followed by 200 mg daily for 21 months
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 23
Study: 22912452

Group type: EXPERIMENTAL
Intervention: Nicarbazin (NCZ) at 125 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salinomycin at 66 mg/kg
Number of subjects: 12
Study: 20706922

Group type: EXPERIMENTAL
Intervention: Paid group intervention
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Paid individual intervention
Number of subjects: 197

Group type: COMPARATOR
Intervention: Unpaid group intervention
Number of subjects: 197
Study: 17548672

Group type: EXPERIMENTAL
Intervention: CAT TT genotype among men diagnosed before age 65
Number of subjects: 724

Group type: COMPARATOR
Intervention: Carriage of five or more risk alleles of MnSOD, CAT, and GPX1
Number of subjects: 724
Study: 15823830

Group type: EXPERIMENTAL
Intervention: Relcovaptan (400 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 12240516

Group type: EXPERIMENTAL
Intervention: Computerized care plan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Paper care plan
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both care plans
Number of subjects: 20
Study: 9578817

Group type: EXPERIMENTAL
Intervention: Radioiodine treatment (RAI) with a median dose of 555 MBq
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study: 8124790

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Alinidine
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 244
Study: 2518859

Group type: EXPERIMENTAL
Intervention: 40 mg famotidine nightly
Number of subjects: 208

Group type: COMPARATOR
Intervention: 150 mg ranitidine b.d.
Number of subjects: 208
Study: 193359

Group type: EXPERIMENTAL
Intervention: ACTH 4-10
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30959747

Group type: EXPERIMENTAL
Intervention: Multi-component intervention promoting physical activity (PA) through group meetings, photo-sharing, and action plans
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Multi-component intervention promoting physical activity (PA)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Waitlisted control group (CG)
Number of subjects: 204
Study: 28286933

Group type: EXPERIMENTAL
Intervention: Nephrostomy tract infiltration of 20 mL saline solution containing 1.5 mg/kg ketamine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group with 20 mL saline solution infiltrated into the nephrostomy tract
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 25217311

Group type: COMPARATOR
Intervention: Conventional instruments (CON)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Patient-specific instruments (PSI)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Computer navigation (NAV)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: All groups (CON, NAV, PSI)
Number of subjects: 81
Study: 23850859

Group type: EXPERIMENTAL
Intervention: Service brokerage intervention (personalised booklet and weekly telephone contact for 4 weeks post-release)
Number of subjects: 1325

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1325
Study: 21510365

Group type: EXPERIMENTAL
Intervention: Improved anatomic-functional model for estimating injury severity and prognosticating traumatic disease course
Number of subjects: 0
Study: 19365397

Group type: EXPERIMENTAL
Intervention: Prophylactic heparin (study group)
Number of subjects: 297

Group type: COMPARATOR
Intervention: No prophylaxis (control group)
Number of subjects: 297